Trial intelligence / Profile preview

Human-derived mesenchymal stem cell conditioned medium for chronic pain

jRCT1051240235Recruiting

Sponsor
Kawagoe Chuo Clinic
Start
Sep 2023
Modality
Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Countries
1
01

Overview

Open-label, single-arm trial of human-derived mesenchymal stem cell conditioned medium in chronic pain, sponsored by Kawagoe Chuo Clinic. Primary endpoint: Improvement of subjective symptoms. Started Sep 2023; status: recruiting.

02

Drugs

human-derived mesenchymal stem cell conditioned medium
03

Conditions

chronic pain

Beyond the preview

Go deeper on jRCT1051240235.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on jRCT1051240235.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call